Skip to main content
Premium Trial:

Request an Annual Quote

Silexion Therapeutics Prices $5M Public Offering

NEW YORK – Silexion Therapeutics said Wednesday that it priced a public offering of its ordinary shares and warrants that is expected to raise $5 million.

The public offering will include 3,703,703 ordinary shares or ordinary share equivalents and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance.

H.C. Wainwright is acting as the exclusive placement agent for the offering, which is expected to close on Jan. 17.

Ramat Gan, Israel-based Silexion plans to use the funds to advance its preclinical studies and for general corporate purposes, according to a filing with the US Securities and Exchange Commission. The firm is studying its small interfering RNA therapy, SIL-204, in preclinical research for two KRAS-driven cancers, colorectal and pancreatic cancer.